Andrew Hester, Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1411 Old Water Works Rd Sw, Fort Payne, AL 35968 Phone: 256-979-1550 Fax: 256-979-1576 |
News Archive
Scientists at University of Limerick are teaming up with Enterprise Ireland to commercialize continuous nanomanufacturing technology which promises to transform the pharmaceutical market.
Adding sulphonylureas (SUs) to metformin remains a commonly used strategy for treating type 2 diabetes, but individual SUs differ and may confer different risks of abnormally low blood sugar, or hypoglycemia. SUs-which include newer generation agents such as gliclazide, glipizide, glimepiride, and glibenclamide-stimulate the production of insulin in the pancreas and increase the effectiveness of insulin in the body.
StemCells, Inc. (NASDAQ:STEM) announced today that it will soon initiate with the University of California, San Francisco (UCSF) Children's Hospital a Phase I clinical trial to evaluate the therapeutic potential of StemCells' proprietary HuCNS-SCĀ® product candidate (purified human neural stem cells) to treat Pelizaeus-Merzbacher Disease (PMD), a myelination disorder that primarily affects infants and young children.
Salix Pharmaceuticals, Ltd. has announced that Salix Pharmaceuticals, Inc. has filed a lawsuit in the United States District Court for the District of New Jersey against Novel Laboratories, Inc. for infringement of the patent protecting OSMOPREP (sodium phosphate monobasic monohydrate, USP and sodium phosphate dibasic anhydrous, USP) Tablets.
› Verified 9 days ago